logo

John Byrd, MD

John Byrd, MD

Hematology Columbus, OH

Director, Division of Hematology, The Ohio State University

Office Address

Office Map
  • 300 W 10th Ave
    Columbus, OH 43210
    Phone: (614) 293-8619
    Fax: (614) 293-6420

Dr. Byrd's Clinical Specialties & Interests

  • Hematology: General Hematology
  • Clinical Interests: Lymphoid Leukemia

Dr. Byrd's Education & Medical Training

  • Walter Reed Army Medical CenterWalter Reed Army Medical CenterFellowship, Hematology/Oncology
  • Walter Reed Army Medical CenterWalter Reed Army Medical CenterResidency, Internal Medicine
  • U of AR Coll of MedUniversity of Arkansas for Medical Sciences College of MedicineMedical School

Dr. Byrd's Certifications & Licensure

  • OH State Medical LicenseOH State Medical LicenseActive through 2013
  • American Board of Internal MedicineAmerican Board of Internal MedicineInternal Medicine, 1994
  • American Board of Internal MedicineAmerican Board of Internal MedicineMedical Oncology, 1997
  • American Board of Internal MedicineAmerican Board of Internal MedicineHematology, 2007

Dr. Byrd's Awards, Honors, & Recognition

  • Centers for Medicare & Medicaid ServicesMeaningful Use Stage 1 CertificationCenters for Medicare & Medicaid Services, 2012
  • The American Society for Clinical InvestigationElected MemberThe American Society for Clinical Investigation, 2005

Dr. Byrd's Clinical Trials

Dr. Byrd's Publications & Presentations

PubMed | Citations by Web of Science®

Lectures

  • Cancer Medicine and HematologyHarvard Medical School ,Department Of Continuing Education, Boston, Massachusetts - 9/29/2013
  • Cancer Medicine and HematologyHarvard Medical School ,Department Of Continuing Education, Boston, Massachusetts - 9/29/2013

Grant Support

  • 2010 Clinical Research Training Institute Summer Workshop
    2010 Clinical Research Training Institute Summer WorkshopNational Heart, Lung, And Blood Institute
    2010 - 2010
  • Lenalidomide As An Immune Modulating Agent For Chronic Lymphocytic Leukemia
    Lenalidomide As An Immune Modulating Agent For Chronic Lymphocytic LeukemiaNational Cancer Institute
    2009 - 2011
  • Administration And Operations
    Administration And OperationsNational Cancer Institute
    2009 - 2011
  • Experimental Therapeutics Of Leukemia
    Experimental Therapeutics Of LeukemiaNational Cancer Institute
    2009 - 2011
  • Translational Training Grant In Experimental Therapeutics
    Translational Training Grant In Experimental TherapeuticsNational Cancer Institute
    2008 - 2011
  • Innate Immune Therapies In B Cell Malignancies
    Innate Immune Therapies In B Cell MalignanciesNational Cancer Institute
    2007 - 2011
  • Clinical Investigation Of Epigenetic Therapy
    Clinical Investigation Of Epigenetic TherapyNational Cancer Institute
    2006 - 2010
  • Molecular Markers: Response To Chemo-Immunotherapy In C*
    Molecular Markers: Response To Chemo-Immunotherapy In C*National Cancer Institute
    2005 - 2005
  • Epigenetic Targeted Therapy For Chronic Lymphocytic Leu*
    Epigenetic Targeted Therapy For Chronic Lymphocytic Leu*National Cancer Institute
    2005 - 2005
  • Clinical Trial Office
    Clinical Trial OfficeNational Cancer Institute
    2005 - 2009
  • Chronic Lymphocytic Leukemia:Epigenetic Targeted Therapy
    Chronic Lymphocytic Leukemia:Epigenetic Targeted TherapyNational Cancer Institute
    2004 - 2004
  • Molecular Markers: Response To Chemo-Immunotherapy In CL
    Molecular Markers: Response To Chemo-Immunotherapy In CLNational Cancer Institute
    2004 - 2004
  • Hu1d10 In CLL: Clinical And Laboratory Studies
    Hu1d10 In CLL: Clinical And Laboratory StudiesNational Cancer Institute
    2003 - 2006
  • Depsipeptide: A Novel Histone Deacytlase Inhibitor In L
    Depsipeptide: A Novel Histone Deacytlase Inhibitor In LNational Cancer Institute
    2002 - 2003
  • Clinical Investigation Of The Innate Immune System
    Clinical Investigation Of The Innate Immune SystemNational Cancer Institute
    2002 - 2002
  • A Phase 1 Study Of Hud10 In Cll/Sll Patients
    A Phase 1 Study Of Hud10 In Cll/Sll PatientsNational Cancer Institute
    2001 - 2002
  • Cancer And Leukemia Group B
    Cancer And Leukemia Group BNational Cancer Institute
    1999 - 1999

Dr. Byrd's Professional Memberships

Insurance Accepted

  • Aetna Choice POS II
  • Aetna HMO
  • Anthem Blue Access PPO
  • Anthem Blue Preferred HMO
  • AvMed Health Open Access
  • BCBS Blue Card PPO
  • BCBS Florida BlueCare HMO
  • BCBS Florida NetworkBlue
  • BCBS Florida Preferred Patient Care PPO
  • BCBS Illinois PPO
  • CIGNA HMO
  • CIGNA Open Access
  • CIGNA PPO
  • Cofinity PPO
  • Coventry Florida - Employer Group HMO/Open Access
  • Coventry Florida - Employer Group PPO
  • First Health PPO
  • Great West PPO
  • HealthAmerica HealthAssurance PPO
  • Humana ChoiceCare Network PPO
  • Medical Mutual of Ohio SuperMed Plus
  • Medical Mutual of Ohio SuperMed POS
  • Multiplan PHCS PPO
  • Multiplan PPO
  • United - River Valley Neighborhood Health Partnership
  • United Healthcare - Direct Choice Plus POS
  • United Healthcare - Direct Options PPO

Physicians, view Dr. Byrd's full Doximity profile to:

  • Trade HIPAA-secure messages
  • Send and receive online faxes
  • Refer a patient
  • See their complete CV